Market Closed -
Nasdaq
21:30:01 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
23.13
USD
|
+1.80%
|
|
+8.19%
|
-15.03%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,611
|
5,327
|
2,692
|
2,159
|
1,836
|
-
|
-
|
Enterprise Value (EV)
1 |
4,318
|
4,367
|
1,613
|
969.4
|
1,066
|
1,478
|
1,836
|
P/E ratio
|
-19.5
x
|
-13.8
x
|
-9.47
x
|
-15.8
x
|
-4.25
x
|
-4.54
x
|
-4.23
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
192,105
x
|
103
x
|
44.2
x
|
5.72
x
|
29
x
|
28.6
x
|
32
x
|
EV / Revenue
|
179,928
x
|
84.2
x
|
26.5
x
|
2.57
x
|
16.8
x
|
23
x
|
32
x
|
EV / EBITDA
|
-
|
-11.3
x
|
-4.97
x
|
-6.2
x
|
-2.47
x
|
-3.3
x
|
-3.87
x
|
EV / FCF
|
-38.5
x
|
-38.6
x
|
-61.1
x
|
-5.3
x
|
-2.91
x
|
-3.96
x
|
-5.51
x
|
FCF Yield
|
-2.6%
|
-2.59%
|
-1.64%
|
-18.9%
|
-34.4%
|
-25.3%
|
-18.2%
|
Price to Book
|
15.5
x
|
6.19
x
|
3.66
x
|
2.14
x
|
2.17
x
|
2.75
x
|
-
|
Nbr of stocks (in thousands)
|
56,474
|
66,849
|
68,821
|
79,326
|
79,383
|
-
|
-
|
Reference price
2 |
81.64
|
79.69
|
39.11
|
27.22
|
23.13
|
23.13
|
23.13
|
Announcement Date
|
15/03/21
|
28/02/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.018
|
0.024
|
51.84
|
60.92
|
377.7
|
63.42
|
64.3
|
57.46
|
EBITDA
1 |
-
|
-
|
-385
|
-324.3
|
-156.5
|
-431.5
|
-448.4
|
-474
|
EBIT
1 |
-75.15
|
-132.8
|
-392.5
|
-338.5
|
-176.5
|
-465.5
|
-459.2
|
-493
|
Operating Margin
|
-417,522.22%
|
-553,166.67%
|
-757.01%
|
-555.61%
|
-46.73%
|
-734.02%
|
-714.15%
|
-858.1%
|
Earnings before Tax (EBT)
1 |
-78.33
|
-194.6
|
-370.6
|
-260.2
|
-131.2
|
-456.8
|
-447.3
|
-509
|
Net income
1 |
-91.04
|
-195.9
|
-370.6
|
-289.1
|
-132.5
|
-452.3
|
-446.7
|
-491.5
|
Net margin
|
-505,777.78%
|
-816,120.83%
|
-714.91%
|
-474.54%
|
-35.09%
|
-713.22%
|
-694.82%
|
-855.45%
|
EPS
2 |
-2.489
|
-4.190
|
-5.770
|
-4.130
|
-1.720
|
-5.442
|
-5.094
|
-5.466
|
Free Cash Flow
1 |
-84.52
|
-112.1
|
-113.1
|
-26.42
|
-182.9
|
-366.5
|
-373.5
|
-333.3
|
FCF margin
|
-469,561.11%
|
-467,075%
|
-218.11%
|
-43.37%
|
-48.43%
|
-577.89%
|
-580.91%
|
-580.16%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
15/03/21
|
28/02/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.763
|
51.07
|
8.432
|
16.65
|
15.8
|
20.04
|
24.21
|
20.12
|
17.19
|
316.2
|
14.66
|
14.72
|
14.77
|
14.83
|
-
|
EBITDA
1 |
-
|
-60.85
|
-72.91
|
-
|
-87.83
|
-85.04
|
-
|
-97.33
|
-103.1
|
138.2
|
-109.5
|
-110.2
|
-111
|
-111.8
|
-
|
EBIT
1 |
-69.63
|
-63.48
|
-76.22
|
-81.97
|
-91.3
|
-88.98
|
-98.93
|
-102.1
|
-108.3
|
132.9
|
-124.3
|
-123.5
|
-121.6
|
-124.6
|
-115
|
Operating Margin
|
-9,126.34%
|
-124.31%
|
-904%
|
-492.23%
|
-577.9%
|
-444.1%
|
-408.66%
|
-507.79%
|
-629.72%
|
42.02%
|
-847.85%
|
-839.35%
|
-823.06%
|
-840.32%
|
-
|
Earnings before Tax (EBT)
1 |
-28.12
|
-64.71
|
-69.21
|
-71.95
|
-81.66
|
-37.35
|
-96.46
|
-82.78
|
-96.09
|
144.2
|
-120.8
|
-117
|
-117.1
|
-121.2
|
-114
|
Net income
1 |
-28.12
|
-64.71
|
-69.21
|
-71.95
|
-109.6
|
-38.35
|
-96.46
|
-82.78
|
-96.09
|
142.8
|
-119.3
|
-115.3
|
-115.4
|
-118.6
|
-114
|
Net margin
|
-3,685.19%
|
-126.71%
|
-820.85%
|
-432.08%
|
-693.56%
|
-191.39%
|
-398.46%
|
-411.49%
|
-558.88%
|
45.16%
|
-813.29%
|
-783.65%
|
-781.24%
|
-800.16%
|
-
|
EPS
2 |
-0.4200
|
-0.9500
|
-1.010
|
-1.020
|
-1.560
|
-0.5400
|
-1.330
|
-1.080
|
-1.220
|
1.730
|
-1.436
|
-1.390
|
-1.378
|
-1.397
|
-1.350
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/11/21
|
28/02/22
|
09/05/22
|
09/08/22
|
07/11/22
|
28/02/23
|
10/05/23
|
08/08/23
|
08/11/23
|
27/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
292
|
960
|
1,078
|
1,190
|
770
|
358
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-84.5
|
-112
|
-113
|
-26.4
|
-183
|
-366
|
-374
|
-333
|
ROE (net income / shareholders' equity)
|
-
|
-881%
|
-69.1%
|
-37.1%
|
-15.5%
|
-55.2%
|
-80.5%
|
-105%
|
ROA (Net income/ Total Assets)
|
-56.4%
|
-64.5%
|
-38.5%
|
-20.5%
|
-11.7%
|
-33.5%
|
-38.1%
|
-
|
Assets
1 |
161.6
|
303.9
|
963.1
|
1,408
|
1,134
|
1,350
|
1,173
|
-
|
Book Value Per Share
2 |
-3.920
|
5.250
|
12.90
|
10.70
|
12.70
|
10.70
|
8.400
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-1.030
|
0.3200
|
-1.930
|
-4.100
|
-3.840
|
-
|
Capex
1 |
12.5
|
16.4
|
46.8
|
49
|
33.7
|
30.1
|
31.2
|
30.7
|
Capex / Sales
|
69,544.44%
|
68,154.17%
|
90.29%
|
80.35%
|
8.93%
|
47.46%
|
48.53%
|
53.38%
|
Announcement Date
|
30/03/20
|
15/03/21
|
28/02/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
23.13
USD Average target price
49.54
USD Spread / Average Target +114.17% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.03% | 1.84B | | +25.69% | 47.9B | | +47.36% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|